Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Glukosmönster hos infertila kvinnor som får assisterad reproduktion med hjälp av kontinuerlig glukosövervakning

17 november 2026 uppdaterad av: Jian Zhou, Shanghai 6th People's Hospital

Glukosmönster hos infertila kvinnor som får assisterad reproduktion: En prospektiv studie med kontinuerlig glukosövervakning

No studies have been seen on glucose variation during medication for assisted reproduction. The aim of this study is to continuously observe glucose variation during assisted reproduction treatment using continuous glucose monitoring (CGM), and to further explore whether glucose variation will affect the outcomes related to assisted reproduction.

Studieöversikt

Status

Aktiv, inte rekryterande

Betingelser

Intervention / Behandling

Detaljerad beskrivning

Infertility is a growing global health concern and affects approximately 20% of couples of reproductive age. As a result, the use of assisted reproductive technologies (ART) is becoming more prevalent. This study could serve as a basis for the interpretation of glucose levels with respect to these people undergoing ART regimen. Moreover, the success rate of ART still needs to be further improved. Key challenges include optimizing the hormonal components of ART regimens and determining the ideal treatment duration. This study might provide insights into the potential benefits of monitoring glucose levels at specific points during ART cycles (which is not usually performed in routine practice) and help clinicians tailor ART regimen to minimize glucose variation, ultimately improving clinical pregnancy and live birth rates. Additionally, the findings might support integrating CGM into the clinical practice of ART, enhancing individualized patient care.

Studietyp

Interventionell

Inskrivning (Beräknad)

100

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200233
        • Shanghai Sixth People's Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 40 år (Vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Kvinna

Beskrivning

Inclusion Criteria:

  1. Informed consent and voluntary participation in this study;
  2. Age ≥ 18 years and ≤40 years old;
  3. Infertile patients who will undergo their first or second cycle of in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) at the study center;
  4. The chosen ovulation promotion regimens is the GnRH antagonist regimen/progesterone-promoting ovulation under hyperprogesterone state (PPOS) regimen.

Exclusion Criteria:

  1. Recent infections (excluding viral infections of the reproductive system such as HPV);
  2. Recent glucocorticoid treatment or chemotherapy;
  3. Clinical conditions affecting the outcome of assisted reproduction, including repeated implantation failure, recurrent spontaneous abortion, history of unilateral oophorectomy, uterine malformations, and parental karyotype abnormalities;
  4. Participants were unable to tolerate tape adhesive around sensor placement area, or with medically documented allergy towards the adhesive (glue) of plasters, or with serious skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) around sensor placement area.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Övrig
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: wearing continuous glucose monitorings

Patients will wear two FreeStyle Libre Pro Flash CGM (Abbott Diabetes Care, Alameda, CA, USA) to ensure continuous tracking of blood glucose levels at key time points throughout the ovarian stimulation.

Each patient will participate in the group only once and wear two FreeStyle Libre Pro Flash CGM (Abbott Diabetes Care, Alameda, CA, USA), which record glucose readings for up to 14 days.

Following the initial consultation and before initiating the ovulation induction protocol, the first CGM sensor will be placed to collect baseline data. Upon entering the ovulation induction cycle, patients will return to the hospital on the 2nd or 3rd day of menstruation, at which point the first CGM sensor will be removed, and the second sensor will be applied. This second sensor will be removed after 14 days.

In summary, this protocol ensures continuous tracking of blood glucose levels at key time points throughout the ovarian stimulation.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Mean sensor glucose (MSG)
Tidsram: Through study completion (during assisted reproductive treatment period,about 2 months)

Mean of daily continuous 24-h blood glucose

Through study completion (during assisted reproductive treatment period,about 2 months)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
time in tight range(3.9~7.8mmol/L, %)
Tidsram: Through study completion (during assisted reproductive treatment period,about 2 months)

Percentage of time within glucose level of 3.9-7.8 mmol/L (70-140 mg/dL) measured by CGM

Through study completion (during assisted reproductive treatment period,about 2 months)
Time below range (<3.9mmol/L, %)
Tidsram: Through study completion (during assisted reproductive treatment period,about 2 months)

Percentage of time below glucose level of 3.9 mmol/L (70 mg/dL) measured by CGM.

Through study completion (during assisted reproductive treatment period,about 2 months)
Time above range (>7.8mmol/L, %)
Tidsram: Through study completion (during assisted reproductive treatment period,about 2 months)

Percentage of time above glucose level of 7.8 mmol/L (140 mg/dL) measured by CGM

Through study completion (during assisted reproductive treatment period,about 2 months)
Coefficient of variation (CV)
Tidsram: Through study completion (during assisted reproductive treatment period,about 2 months)

Standard deviation divided by mean glucose level measured by CGM

Through study completion (during assisted reproductive treatment period,about 2 months)
Standard deviation (SD)
Tidsram: Through study completion (during assisted reproductive treatment period,about 2 months)

Standard deviation of blood glucose measurements during CGM

Through study completion (during assisted reproductive treatment period,about 2 months)

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Number of oocytes retrieved
Tidsram: Through study completion (during assisted reproductive treatment period,about 2 months)

The number of oocytes obtained under ultrasound guidance

Through study completion (during assisted reproductive treatment period,about 2 months)
Oocyte retrieval rate
Tidsram: Through study completion (during assisted reproductive treatment period,about 2 months)

Oocyte Retrieval Rate = Number of Oocytes Retrieved / Number of Follicles

Through study completion (during assisted reproductive treatment period,about 2 months)
Number of MII oocytes
Tidsram: Through study completion (during assisted reproductive treatment period,about 2 months)

The number of metaphase II oocytes that have nuclear maturity at the time of injection

Through study completion (during assisted reproductive treatment period,about 2 months)
Rate of MII oocytes
Tidsram: Through study completion (during assisted reproductive treatment period,about 2 months)

the proportion of oocytes that have nuclear maturity at the time of injection

Through study completion (during assisted reproductive treatment period,about 2 months)
Rate of high-quality embryos
Tidsram: Through study completion (during assisted reproductive treatment period,about 2 months)

the proportion of Day 2 and Day 3 embryos with high score or grade

Through study completion (during assisted reproductive treatment period,about 2 months)
Biochemical pregnancy rate
Tidsram: Through study completion (during assisted reproductive treatment period,about 6 months)

The proportion of pregnancies confirmed by the detection of hCG in serum or urine, but without ultrasound confirmation of a gestational sac or fetal heartbeat.

Through study completion (during assisted reproductive treatment period,about 6 months)
Clinical pregnancy rate
Tidsram: Through study completion (during assisted reproductive treatment period,about 6 months)

The proportion of pregnancies confirmed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy

Through study completion (during assisted reproductive treatment period,about 6 months)
Miscarriage rate
Tidsram: Through study completion, about 1 year

The proportion of pregnancies that end spontaneously before 28 weeks of gestation after confirmation of clinical pregnancy

Through study completion, about 1 year
Live Birth Rate
Tidsram: Through study completion, 18 months

The proportion of successful deliveries resulting in a live-born infant.

Through study completion, 18 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

26 mars 2025

Primärt slutförande (Faktisk)

30 juni 2026

Avslutad studie (Beräknad)

30 april 2027

Studieregistreringsdatum

Först inskickad

3 mars 2025

Först inskickad som uppfyllde QC-kriterierna

6 mars 2025

Första postat (Faktisk)

7 mars 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

17 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Ja

produkt tillverkad i och exporterad från U.S.A.

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera